The Editor's Roundtable: Closing the Clinical Practice Gap—Using Evidence-Based Treatments for Managing Lipids

Abstract

Dr. Roberts has received honoraria for speaking from erck & Co., Inc.; and AstraZeneca Pharmaceuticals, LP, ilmington, Delaware. Dr. Gotto has received honoraria and fees for consulting rom Genentech, San Francisco, California; Martek, Columia, Maryland; Kowa Company, Ltd., Torrance, California; erck & Co., Inc., Merck/Schering-Plough; honoraria from he boards of directors of Aegerion Pharmaceuticals, ridgewater, New Jersey, and Arisaph Pharmaceuticals, oston, Massachusetts; honoraria from the advisory boards f E.I. duPont de Nemours and Company, Wilmington, elaware, and Novartis Pharmaceuticals Corporation, asel, Switzerland. Dr. Guyton has received speaker honorarium from erck & Co., Inc.; Abbott Laboratories, Abbott Park, Illiois; Schering-Plough Corporation; AstraZeneca Pharmaeuticals, LP; course director honorarium from Merck & o., Inc.; Abbott Laboratories; Schering-Plough Corporaion; Sanofi-Aventis, Paris, France; and research grants rom Merck & Co., Inc.; Abbott Laboratories; Genzyme orporation Cambridge, Massachusetts; Sanofi-Aventis; nd is a stockholder of Eli Lilly, Indianapolis, Indiana. Dr. LaRosa has received speaker and consultant honoarium from Pfizer, Inc., New York, New York, and Merck Co., Inc.; and consultant honorarium from Bayer Healthare Pharmaceuticals, Leverkusen, Germany. Dr. Viggiani has no relevant financial relationships to isclose.